{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:50:30Z","timestamp":1791355830448,"version":"4.3.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune inflammatory demyelinating disorder of the central nervous system with a broad clinical spectrum that includes brainstem syndromes. Evidence supporting neonatal Fc receptor (FcRn) inhibition in MOGAD remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 37-year-old woman presented with a MOGAD-associated brainstem syndrome characterized by diplopia, ocular-motor abnormalities, right facial weakness, and gait instability. Brain MRI demonstrated a lesion in the right middle cerebellar peduncle near the fourth ventricle. CSF analysis showed 2 leukocytes\/\u00b5L, 0 erythrocytes\/\u00b5L, normal protein (0.328 g\/L), a type II oligoclonal-band pattern, and an elevated IgG index of 1.8 (reference value, &amp;lt;0.7), supporting intrathecal IgG synthesis. Serum MOG-IgG was positive by live cell-based assay. High-dose corticosteroids were discussed, but the patient declined them because of concerns regarding adverse effects. IVIG was subject to intermittent local shortage and substantial financial burden, while PLEX was considered disproportionate to the clinical severity. The patient received individualized off-label intravenous efgartigimod (20 mg\/kg on Days 1 and 5) and improved clinically. After the second relapse, the same efgartigimod regimen was repeated, and low-dose oral prednisone and MMF were initiated for relapse prevention. Prednisone was discontinued approximately 5 months after initiation, whereas MMF was continued as maintenance therapy. At follow-up approximately 18 months after discharge, the patient was clinically asymptomatic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case documents a recognized brainstem MOGAD presentation with clinical improvement temporally associated with individualized off-label FcRn inhibition. Interpretation should consider the single-case design, absence of a comparator, rehabilitation, low-dose prednisone and MMF initiated for relapse prevention, and the natural course of the disease. This observation provides preliminary clinical context for prospective evaluation of FcRn inhibition but is insufficient to establish efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1896346","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:58:42Z","timestamp":1791352722000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efgartigimod for acute attacks of brainstem MOGAD followed by mycophenolate mofetil maintenance: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Fangshu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miduo","family":"Tan","sequence":"additional","affiliation":[{"name":"Medical Center of Digestive Disease, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/ijms22010100","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: Current insights into the disease pathophysiology, diagnosis and management","volume":"22","author":"Ambrosius","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03108-y","article-title":"MOG antibody-associated optic neuritis","volume":"38","author":"Jeyakumar","year":"2024","journal-title":"Eye (Lond)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflamm"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejpn.2020.10.006","article-title":"E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231184738","article-title":"Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease","volume":"29","author":"Lotan","year":"2023","journal-title":"Mult Scler"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000213903","article-title":"Outcomes after acute plasma exchange for myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"105","author":"Thakolwiboon","year":"2025","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-019-00375-8","article-title":"Myelin oligodendrocyte glycoprotein-IgG contributes to oligodendrocytopathy in the presence of complement, distinct from astrocytopathy induced by AQP4-IgG","volume":"35","author":"Fang","year":"2019","journal-title":"Neurosci Bull"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/jci97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001134","article-title":"Antineonatal Fc receptor antibody treatment ameliorates MOG-IgG-associated experimental autoimmune encephalomyelitis","volume":"9","author":"Remlinger","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1624660","article-title":"Case report: Efgartigimod as an additional therapy for MOG antibody-associated disease overlapping GFAP-IgG","volume":"16","author":"Zhu","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10072-026-09000-9","article-title":"Successful treatment with efgartigimod as rescue therapy in acute attack of MOGAD: a case report","volume":"47","author":"Li","year":"2026","journal-title":"Neurol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1793153","article-title":"Efficacy and safety of efgartigimod as an add-on therapy in patients with NMOSD and MOGAD at the acute attack phase","volume":"17","author":"Yin","year":"2026","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12883-025-04063-1","article-title":"Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the neuro intensive care unit","volume":"25","author":"Shi","year":"2025","journal-title":"BMC Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123597","article-title":"Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks","volume":"371","author":"Liu","year":"2025","journal-title":"Life Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.neurol.2025.04.012","article-title":"French guidelines for the diagnosis and management of MOG antibody-associated disease","volume":"181","author":"Giorgi","year":"2025","journal-title":"Rev Neurol (Paris)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1896346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:58:42Z","timestamp":1791352722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1896346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2026.1896346"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1896346","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1896346"}}